Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa

Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa

Human immunodeficiency virus (HIV)-exposed infants may be at increased risk of vaccine-preventable disease. This study was conducted as a post-licensure commitment in this population to evaluate the primary series, antibody persistence, and booster response to a licensed fully liquid hexavalent vacc...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Anthonet Koen, Shabir Madhi, Olga Lyabis, Emmanuel Vidor, Beverley Cowper, Thinus Marais, Dhaval Patel, Claire Vigne
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Taylor & Francis Group 2021-06-01
Sarja:Human Vaccines & Immunotherapeutics
Aiheet:
booster
hexavalent
historical comparison
hiv-exposed
hiv-infected
primary series
vaccine
Linkit:http://dx.doi.org/10.1080/21645515.2020.1839289

Internet

http://dx.doi.org/10.1080/21645515.2020.1839289

Samankaltaisia teoksia